A comprehensive and collaborative strategy to enable the investigation of new uses of approved and abandoned drug compounds could advance translational research.
"Please read this paper; it is an interesting initiative to get drugs off the shelves of Pharma companies and into the hands of investigators and hopefully into clinical trials. The biggest potential benefit of this will be progressive MS'ers. If big Pharma have gone cold on progressive MS, we certainly haven't."